Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices

Background information: The utilization of transdermal buprenorphine rapidly increased in the past 10 years, since the first item launched in 2002. The increase utilization was suggested mainly causing by expending use for chronic pain control. Aims: This preliminary study assessed the utilizatio...

Full description

Bibliographic Details
Main Author: Zin, Che Suraya
Format: Proceeding Paper
Language:English
Published: 2012
Subjects:
Online Access:http://irep.iium.edu.my/35827/
http://irep.iium.edu.my/35827/1/Transdermal_Buprenorphine.pdf
_version_ 1848781116639543296
author Zin, Che Suraya
author_facet Zin, Che Suraya
author_sort Zin, Che Suraya
building IIUM Repository
collection Online Access
description Background information: The utilization of transdermal buprenorphine rapidly increased in the past 10 years, since the first item launched in 2002. The increase utilization was suggested mainly causing by expending use for chronic pain control. Aims: This preliminary study assessed the utilization trend of both low (5, 10 or 20 μg/hour for 7 days) and high (35, 52.5 or 70 μg/hour for 4 days) dose of transdermal buprenorphine to explore the leading use items. Methods: This cross sectional study was conducted from 2002 to 2010 using the UK Clinical Practice Research Datalink which consists of primary care data from 639 practices. Transdermal buprenorphine prescriptions were extracted using specific product codes. Total and annual numbers of prescriptions were stratified by transdermal formulation doses and analyzed by simple linear regression. Result: 339772 transdermal buprenorphine prescriptions were prescribed for 97035 patients from 2002 to 2010. Of these 81% (n=274613) and 19% (n=65159) of the prescriptions were prescribed for low- and high-dose formulations respectively. Transdermal buprenorphine 5 μg/h (34%) was the most frequently prescribed item followed by 10 μg/h (31%), 20 μg/h (16%), 35 μg/h (9%), 52.5 μg/h (5%) and 70 μg/h (5%). Annual number of prescriptions for all transdermal items significantly increased (11543%) during study period (P<0.001). Conclusion: Low-doses (5 μg/h and 10 μg/h) transdermal buprenorphine were the most frequently prescribed and significantly contributed to the overall increased utilization of transdermal buprenorphine. Further research is required to analyze treatment indications and factors influence prescribing decisions.
first_indexed 2025-11-14T15:44:27Z
format Proceeding Paper
id iium-35827
institution International Islamic University Malaysia
institution_category Local University
language English
last_indexed 2025-11-14T15:44:27Z
publishDate 2012
recordtype eprints
repository_type Digital Repository
spelling iium-358272014-03-10T01:46:11Z http://irep.iium.edu.my/35827/ Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices Zin, Che Suraya RS Pharmacy and materia medica Background information: The utilization of transdermal buprenorphine rapidly increased in the past 10 years, since the first item launched in 2002. The increase utilization was suggested mainly causing by expending use for chronic pain control. Aims: This preliminary study assessed the utilization trend of both low (5, 10 or 20 μg/hour for 7 days) and high (35, 52.5 or 70 μg/hour for 4 days) dose of transdermal buprenorphine to explore the leading use items. Methods: This cross sectional study was conducted from 2002 to 2010 using the UK Clinical Practice Research Datalink which consists of primary care data from 639 practices. Transdermal buprenorphine prescriptions were extracted using specific product codes. Total and annual numbers of prescriptions were stratified by transdermal formulation doses and analyzed by simple linear regression. Result: 339772 transdermal buprenorphine prescriptions were prescribed for 97035 patients from 2002 to 2010. Of these 81% (n=274613) and 19% (n=65159) of the prescriptions were prescribed for low- and high-dose formulations respectively. Transdermal buprenorphine 5 μg/h (34%) was the most frequently prescribed item followed by 10 μg/h (31%), 20 μg/h (16%), 35 μg/h (9%), 52.5 μg/h (5%) and 70 μg/h (5%). Annual number of prescriptions for all transdermal items significantly increased (11543%) during study period (P<0.001). Conclusion: Low-doses (5 μg/h and 10 μg/h) transdermal buprenorphine were the most frequently prescribed and significantly contributed to the overall increased utilization of transdermal buprenorphine. Further research is required to analyze treatment indications and factors influence prescribing decisions. 2012-10-03 Proceeding Paper PeerReviewed application/pdf en http://irep.iium.edu.my/35827/1/Transdermal_Buprenorphine.pdf Zin, Che Suraya (2012) Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices. In: FIP Centennial Congress, 3-8 October 2012, Amsterdam, Netherlands.
spellingShingle RS Pharmacy and materia medica
Zin, Che Suraya
Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title_full Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title_fullStr Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title_full_unstemmed Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title_short Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices
title_sort transdermal buprenorphine: utilization trends in united kingdom primary care practices
topic RS Pharmacy and materia medica
url http://irep.iium.edu.my/35827/
http://irep.iium.edu.my/35827/1/Transdermal_Buprenorphine.pdf